Securities code: 002925 securities abbreviation: Xiamen Intretech Inc(002925) Announcement No.: 2022-001 Xiamen Intretech Inc(002925)
Announcement on resolutions of the 16th meeting of the 4th board of directors
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
The 16th meeting of the 4th board of directors of Xiamen Intretech Inc(002925) (hereinafter referred to as “the company”) was held in Conference Room 806, building 3, Xiamen Intretech Inc(002925) Chuang Shenzhen New Industries Biomedical Engineering Co.Ltd(300832) Park, No. 100, Dongfu West Road, Haicang District, Xiamen on December 30, 2021. The meeting notice was delivered by e-mail on December 27, 2021. There were 9 directors who should attend the meeting, 9 actually attended the meeting, all directors attended the meeting, and the company’s supervisors and senior managers attended the meeting as nonvoting delegates. The meeting was presided over by Mr. Lin Songhua, chairman of the company. The convening and convening of the meeting comply with the company law of the people’s Republic of China, the articles of association and other relevant provisions.
After careful consideration by the directors attending the meeting, the following resolutions were adopted by means of communication voting: I. the meeting considered and adopted the proposal on the use of some idle self owned funds for cash management by 9 votes in favor, 0 votes against and 0 abstentions.
In order to improve the use efficiency of funds, make rational use of some idle self owned funds and increase the company’s income, on the premise of ensuring that the daily operation of the company is not affected, the board of directors agrees that the company (including subsidiaries, the same below) uses idle self owned funds of no more than RMB 2.3 billion for cash management, and plans to purchase high security, good liquidity Financial products with a single product investment period of no more than 12 months. The service life is 12 months from the date of deliberation and approval by the board of directors of the company. Within the above service life and limit, the funds can be used on a rolling basis. The board of directors agrees to authorize the president on duty and his authorized persons to exercise investment decision-making power within the above limit and sign relevant legal documents, which shall be organized, implemented and managed by the chief financial officer.
The independent directors of the company expressed independent opinions on the matter.
For details, please refer to securities times, China Securities Journal and cninfo.com on the same day（ http://www.cn.info.com..cn. ）Announcement on using some idle self owned funds for cash management disclosed.
2、 The meeting deliberated and adopted the proposal on carrying out forward foreign exchange settlement and sales business with 9 affirmative votes, 0 negative votes and 0 abstention votes.
In order to effectively avoid and prevent foreign exchange market risks, the board of directors agreed to the feasibility analysis report on carrying out forward foreign exchange settlement and sales business submitted by the company’s management, and agreed that the company (including subsidiaries) would carry out forward foreign exchange settlement and sales business with a total amount of no more than US $1 billion in 2022. The business period shall be valid within one year from the date of deliberation and approval by the general meeting of shareholders of the company. Propose to the general meeting of shareholders to authorize the president on duty and his authorized person to sign relevant transaction documents.
The independent directors of the company expressed independent opinions on the matter.
See the company’s securities times, China Securities Journal and cninfo.com for details（ http://www.cn.info.com..cn. ）Disclosed the feasibility analysis report on carrying out forward foreign exchange settlement and sales business and the announcement on carrying out forward foreign exchange settlement and sales business.
This proposal needs to be submitted to the first extraordinary general meeting of shareholders of the company in 2022 for deliberation.
3、 The meeting deliberated and adopted the proposal on convening the first extraordinary general meeting of shareholders in 2022 by 9 affirmative votes, 0 negative votes and 0 abstention votes.
The board of directors of the company decided to hold the first extraordinary general meeting of shareholders in 2022 by combining on-site voting and online voting at 15:00 p.m. on Thursday, January 20, 2022 in Conference Room 806, building 3, Chuang Shenzhen New Industries Biomedical Engineering Co.Ltd(300832) Park, No. 100, Dongfu West Road, Haicang District, Xiamen. As of January 13, 2022 (equity registration date), all shareholders of the company registered have the right to attend and vote at the general meeting of shareholders. Shareholders who are unable to attend the meeting in person for some reason can entrust an agent to attend and vote on their behalf, and the agent does not need to be a shareholder of the company.
For details, please refer to securities times, China Securities Journal and cninfo.com on the same day（ http://www.cn.info.com..cn. ）Notice on convening the first extraordinary general meeting of shareholders in 2022 disclosed.
It is hereby announced.
Xiamen Intretech Inc(002925) board of directors
January 4, 2022
